Quantum-Si (QSI) Q1 2026 earnings review
Revenue Collapses as the 'Transition Year' Begins
Quantum-Si's intentional Osborne Effect is in full swing. By pre-announcing the next-generation Proteus system at a $425,000 list price, the company essentially froze demand for its legacy Platinum instruments. Q1 2026 revenue collapsed 69% YoY to a meager $258,000, missing the run-rate needed to achieve even their lowered historical marks. However, management views 2026 as an intentional transition year, sacrificing near-term sales to focus R&D on the upcoming Proteus launch. With $190.4 million in cash, they have the runway to execute, but the entire investment thesis now hinges on a flawless end-of-2026 product launch.
🐂 Bull Case
The company successfully completed automated sequencing runs on integrated Proteus prototypes and detected 17 amino acids, keeping the late-2026 commercial launch firmly on track.
With $190.4M in cash and marketable securities, QSI's balance sheet acts as a massive shock absorber. The company is funded through Q2 2028, eliminating near-term dilution risk.
🐻 Bear Case
Revenue has effectively flatlined. $258k in quarterly revenue for a public life sciences company represents a reversing trend in market traction for their current generation tech.
The $425k Proteus system faces a challenging macro capital-equipment environment. If the launch is delayed or adoption is slower than expected, the entire narrative breaks.
⚖️ Verdict: 🔴
Bearish. While the R&D progress on Proteus is commendable, the evaporation of existing revenue streams and compression of gross margins (down to 29%) leaves the company highly vulnerable to single-product execution risk.
Key Themes
Proteus R&D is the Sole Growth Catalyst
Technological innovation is QSI's primary driver. Management announced successful, automated sequencing on fully integrated Proteus instruments without user intervention. The current developmental kit can now detect 17 amino acids (approaching the full 20). If they deliver on the $425,000 system by late 2026, it will provide the throughput and automation needed to penetrate core labs.
The Osborne Effect is Crushing Current Financials
By publicly pivoting entirely to Proteus, QSI killed the Platinum Pro. While management calls this a 'deliberate strategic action,' it contradicts the prior quarter's narrative that instrument placements and the V4/V3 kits would maintain a baseline of consumable revenue. Instead, product revenue fell to $216k and service revenue to $42k. The core base is not stabilizing.
Shifting the Spend: R&D Up, SG&A Down
Total operating expenses are stable, but the mix is changing. QSI cut SG&A by 19% YoY (down to $9.6M) while raising R&D by 6% (up to $14.5M). This is the exact correct capital allocation strategy for a pre-product-launch technology company: starve the stagnant sales channels and feed the engineers.
Macro Pressures on Capital Budgets
The company has cited NIH funding uncertainty and capital equipment freezes in U.S. academic labs over the past four quarters. A tough macro environment is a terrible time to launch a $425k capital-intensive instrument, risking elongated sales cycles for Proteus in 2027.
Gross Margins Reversing on Low Volume
Gross margin completely decoupled from prior historical norms, compressing to 29% in 26Q1 (down from 58% in 25Q1 and an average of 47% in FY25). This deceleration highlights the severe diseconomies of scale QSI is facing during this transition year.
Balance Sheet Acts as a Strategic Moat
The company's primary near-term driver is its bank account. With $190.4M in cash and equivalents and an adjusted EBITDA burn rate of ~$20M per quarter, QSI is safely insulated from capital markets until mid-2028. This allows them to ignore the 2026 revenue void and focus entirely on engineering.
Other KPIs
Accelerating slightly compared to the $19.2M loss in 25Q1, but primarily driven by the top-line evaporation. Adjusted EBITDA came in at negative $20.1M, representing stable and highly predictable quarterly cash burn.
Down sequentially from $215.8M at the end of 2025. This $25.4M reduction reflects the operational burn plus minor working capital adjustments, perfectly tracking management's guidance of ~$93M total cash usage for the year.
Guidance
Decelerating aggressively. This implies flatlining sequential revenue at roughly $250k per quarter for the rest of the year. It confirms that the legacy Platinum Pro business is essentially dead.
Stable. The reiteration of this target shows management is tightly controlling expenses while funneling maximum viable capital toward the Proteus completion.
Stable. At this burn rate, the company will exit 2026 with roughly $120M in cash, plenty of capital to fund the initial 2027 commercial scale-up of Proteus.
Key Questions
Proteus Pre-Orders and Validation
You've guided for a $425k list price to align with 2027 capital budget cycles. Are you currently securing binding pre-orders or letters of intent from the early roadshows to validate this pricing?
Consumables Baseline
With Q1 revenue down to $258k, it appears consumable pull-through from the existing installed base is eroding. Is the legacy installed base abandoning the platform entirely as they wait for Proteus?
Proteus Launch Capabilities
You are currently detecting 17 amino acids. Is the launch of Proteus contingent on hitting all 20, or will you launch at 18 and push software/chemistry updates post-launch?